Global burden of liver disease: 2023 update.
Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS.
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
Chronic hepatitis B and non-alcoholic fatty liver disease: Conspirators or competitors?
Zhang J, Lin S, Jiang D, Li M, Chen Y, Li J, Fan J.
Liver Int. 2020 Mar;40(3):496-508. doi: 10.1111/liv.14369. Epub 2020 Jan 13.
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Kwo PY, Cohen SM, Lim JK.
Am J Gastroenterol. 2017 Jan;112(1):18-35. doi: 10.1038/ajg.2016.517. Epub 2016 Dec 20.
Non-alcoholic steatohepatitis.
Jansen PL.
Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1079-85. doi: 10.1097/00042737-200411000-00001.
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives.
Huang SC, Liu CJ.
Clin Mol Hepatol. 2023 Apr;29(2):320-331. doi: 10.3350/cmh.2022.0422. Epub 2023 Feb 1.
Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.
Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM.
World J Gastroenterol. 2020 Jan 14;26(2):109-133. doi: 10.3748/wjg.v26.i2.109.
Clinical impact and mechanisms of hepatitis B virus infection concurrent with non-alcoholic fatty liver disease.
Tong X, Song Y, Yin S, Wang J, Huang R, Wu C, Shi J, Li J.
Chin Med J (Engl). 2022 Jul 20;135(14):1653-1663. doi: 10.1097/CM9.0000000000002310.
Non-Alcoholic Fatty Liver Disease in HIV Infection.
Macías J, Pineda JA, Real LM.
AIDS Rev. 2017 Jan-Mar;19(1):35-46.
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future.
Chuah KH, Chan WK.
Clin Mol Hepatol. 2023 Apr;29(2):401-403. doi: 10.3350/cmh.2023.0062. Epub 2023 Feb 28.
Review article: non-alcoholic fatty liver disease and hepatitis C--risk factors and clinical implications.
Sanyal AJ.
Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:48-51. doi: 10.1111/j.1365-2036.2005.02596.x.
